Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: Ruffian who wrote (92)	5/21/2007 2:04:44 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

He's definitely one of the better analysts covering Adventrx. He sees the writing on the wall. Kind of like Gilder back in the Qualcomm days. Folate wins, do we want low concentration leucovorin requiring 2 hour infusional delivery or high concentration Cofactor requiring 2 minute bolus injection. Truly, the biggest drawback to 500 mL leucovorin is that it only supplies a POTENTIAL supply of folate via multistage metabolic breakdown. 60 mL Cofactor delivers direct form of folate in minutes, requiring no metabolic conversion. Amazingly, it attracts more 5FU to the tumors to the cancer cells to shut down cancer cell replication, but Cofactor also recovers dna, rna, red and white blood cells in healthy cells since the intracellular concentration of folate is so high in the healthy cells. Higher response rate with elimination of anemia seems to be exactly what the FDA is looking for in first line cancer treatment.